54 results
DEFA14A
ENZ
Enzo Biochem, Inc.
17 Jan 20
Additional proxy soliciting materials
5:29pm
- Funded R&D Robust Licensing Program Generating $154m in Income since 2011 2 $1.3bn 3 in Revenue Derived from IP Commercialization to Date $ 81m … PLATFORM CLINICAL SERVICES Clinical Translation Validation Manufacturing GMP Production Products R&D Diagnostics Unique Integration Develops technologies
8-K/A
EX-99.1
ds3kq1eleg
17 Jan 20
Investor Presentation January 2020
5:29pm
DEFA14A
n635tc xhtp
8 Jan 20
Additional proxy soliciting materials
4:47pm
8-K
EX-99.1
pxpqdx
8 Jan 20
Investor Presentation January 2020
4:39pm
8-K
EX-99.1
tu7msmp34
10 Dec 19
Enzo Biochem Reports Fiscal First Quarter Results
4:30pm
DEFA14A
ka2awg 4h9
5 Dec 19
Additional proxy soliciting materials
5:18pm
DEFA14A
edqbx2
5 Dec 19
Additional proxy soliciting materials
5:12pm
8-K
EX-99.1
ujgwi
5 Dec 19
Enzo Biochem Issues Open Letter to Shareholders
4:36pm
DEFC14A
e7lw369iw6m tu6vo
5 Dec 19
Proxy in contested solicitation
4:22pm
PREC14A
axe6qtowm9sq0
20 Nov 19
Preliminary proxy with contested solicitation
5:26pm
8-K
EX-99.1
p2c64o4l ky2
15 Oct 19
Enzo Biochem Reports Fiscal Fourth Quarter and Full Year Financial Results
4:43pm
8-K
EX-99.1
uueyt3bxg9cw
10 Jun 19
Enzo Biochem Reports Fiscal Third Quarter and Nine Months Operating Results
4:30pm
8-K
EX-99.1
j5t87ktlcmo 0o
11 Mar 19
Reports Progress on Its Investments and Strategic Goals
5:11pm
8-K
EX-99.1
5lb43 s2u5
10 Dec 18
Enzo Biochem Reports Fiscal 2019 First Quarter Results
4:30pm